Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Although no therapies are approved for light chain (AL) amyloidosis, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is considered standard of care. Based on outcomes of daratumumab in multiple myeloma (MM), the phase 3 ANDROMEDA study (NCT03201965) is evaluating daratumumab-CyBorD vs CyBor...

Full description

Saved in:
Bibliographic Details
Published in:Blood
Main Authors: Palladini, Giovanni, Kastritis, Efstathios, Maurer, Mathew S., Zonder, Jeffrey, Minnema, Monique C., Wechalekar, Ashutosh D., Jaccard, Arnaud, Lee, Hans C., Bumma, Naresh, Kaufman, Jonathan L., Medvedova, Eva, Kovacsovics, Tibor, Rosenzweig, Michael, Sanchorawala, Vaishali, Qin, Xiang, Vasey, Sandra Y., Weiss, Brendan M., Vermeulen, Jessica, Merlini, Giampaolo, Comenzo, Raymond L.
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2020
Subjects:
Clinical Trials and Observations
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7332897/
https://ncbi.nlm.nih.gov/pubmed/32244252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019004460
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items